ACR Meeting Abstracts

ACR Meeting Abstracts

Home » Meeting Abstracts » ACR/ARP Annual Meeting 2019

Abstract Number: 2445

Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity

Jessica Walsh1, Alexis Ogdie 2, Kaleb Michaud 3, Steve Peterson 4, Elizabeth Holdsworth 5, Chetan Karyekar 4, Nicola Booth 6, Jessalyn Kemp 7, Soumya Chakravarty 8, Shelly Kafka 9 and Laure Gossec 10, 1Division of Rheumatology, University of Utah, Salt Lake City, UT, 2Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3University of Nebraska Medical Center, Omaha, NE, 4Janssen Global Services, LLC, Horsham, PA, 5Adelphi Real World, Manchester, England, United Kingdom, 6Adelphi Real World, Bollington, United Kingdom, 7Adelphi Real World, Manchester, United Kingdom, 8Janssen Scientific Affairs, LLC; Drexel University College of Medicine, Horsham; Philadelphia, PA, 9Janssen Scientific Affairs, LLC, Horsham, PA, 10Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France

Meeting: ACR/ARP Annual Meeting 2019

Keywords:

Session Information

Date: Tuesday, November 12, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Psoriatic Arthritis, Clinical Features

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: PsA is a chronic, inflammatory disease characterised by peripheral arthritis, axial disease, dactylitis, enthesitis and skin and nail psoriasis.  The impact of skin and joint components of the disease on quality of life and work productivity has been studied (1,2) but the impact of other manifestations has not. This analysis assessed the impact of enthesitis, dactylitis, and axial disease on quality of life and work productivity in PsA patients.

Methods: Cross-sectional study among patients with PsA recruited by rheumatologists and dermatologists in France, Germany, Italy, Spain, UK, and US. Data were collected from Jun-Aug 2018 via physician-completed patient record forms and patient self-completed forms. Physicians recorded (Yes/No) if patients currently presented with enthesitis, dactylitis, inflammatory back pain (IBP), and sacroiliitis (identified by x-ray or MRI). Multiple linear regression analyses were used to examine the impact of these manifestations on patient reported outcomes (PROs) including EQ5D index, EQ5D VAS, HAQ-DI, PsAID12, and WPAI. Models were adjusted for age, gender, number of joints affected, and time since diagnosis. There was no imputation of missing data.

Results: The sample included 1103 patients: mean age 47.6 [SD 13.2] years, 46% were female, 58% were working full time. Mean number of joints affected by PsA was 3.8 (SD 5.2), and 54.9% were receiving biologic treatment. Enthesitis (present in 6.3% of patients), dactylitis (8.0%) and IBP (12.6%) were associated with worse outcomes overall (Table 1); sacroiliitis (3.9%) was linked to worse physical function and quality of life.

Conclusion: In a multi-national, real-world PsA population, enthesitis, dactylitis, IBP, and sacroiliitis were significantly associated with worse patient quality of life and/or work productivity across a range of PROs independent of the number of joints affected. These manifestations should be considered alongside skin and joint components in order to optimize patient outcomes.

References:

  1. Borman P, et al. Clin Rheumatol. 2007;26(3):330–4.
  2. de Vlam K, et al. Rheumatol Ther. 2018;5(2):423–36.

Table 1

Disclosure: J. Walsh, AbbVie, 2, 5, ABBVIE, NOVARTIS, LILLY, AMGEN, UCB, 5, Amgen, 2, 5, Janssen Research & Development, LLC, 2, Lilly, 2, 5, Novartis, 2, 5, Pfizer, 2, 5, PFIZER, ABBVIE, 2, UCB, 5; A. Ogdie, Novartis, 5, 9, Pfizer, 5, 9, Abbvie, 5, Amgen, 5, BMS, 5, Celgene, 5, Corrona, 5, Lilly, 5, Takeda, 5; K. Michaud, FORWARD, The National Databank for Rheumatic Diseases, 3, Pfizer, 2, Pfizer & Rheumatology Research Foundation, 2, Rheumatology Research Foundation, 2, University of Nebraska Medical Center, 3; S. Peterson, Janssen, 1, 3, BMS, 3; E. Holdsworth, None; C. Karyekar, Abbott, 3, BMS, 3, Janssen, 1, 3, Janssen Scientific Affairs, LLC, 3, Novartis, 3; N. Booth, Adelphi Real World, 3; J. Kemp, None; S. Chakravarty, Janssen Research & Development, LLC, 3, Janssen Scientific Affairs, LLC, 1, 3, Johnson & Johnson, 1, 3; S. Kafka, Janssen Research & Development, LLC, 3, Janssen Scientific Affairs, LLC, 1, 3; L. Gossec, Abbvie, 5, AbbVie, 5, Abbvie, Biogen, BMS, Celgene, Lilly, Novartis, Pfizer, SAnofi-Aventis, UCB, 5, Amgen, 5, Biogen, 5, BMS, 2, 5, Celgene, 5, Celgene Corporation, 2, Janssen, 5, Lilly, 2, 5, MSD, 5, Nordic Pharma, 5, Novartis, 5, Pfizer, 2, 5, Sanofi, 5, Sanofi-Aventis, 5, UCB, 5.

To cite this abstract in AMA style:

Walsh J, Ogdie A, Michaud K, Peterson S, Holdsworth E, Karyekar C, Booth N, Kemp J, Chakravarty S, Kafka S, Gossec L. Enthesitis, Dactylitis, and Axial Disease in Psoriatic Arthritis (PsA): Impact on Patient Quality of Life and Work Productivity [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/enthesitis-dactylitis-and-axial-disease-in-psoriatic-arthritis-psa-impact-on-patient-quality-of-life-and-work-productivity/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/enthesitis-dactylitis-and-axial-disease-in-psoriatic-arthritis-psa-impact-on-patient-quality-of-life-and-work-productivity/